EyePoint Pharmaceuticals (EYPT)

• Market cap: $456M
• 1 day: -2.06%
• 5 days: -0.90%
• 1 month: 22.51%
• 3 months: -14.10%
• 6 months: -42.46%
• Year to date: -17.31%
• 1 year: -62.34%
• 5 years: -35.53%
• 10 years: -83.56%
• Sector: Healthcare
• Industry: Biotechnology

About: EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.

Employees: 144

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

168% more repeat investments, than reductions

Existing positions increased: 67 | Existing positions reduced: 25

38% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 21

16% more capital invested

Capital invested by funds: $476M [Q3] → $553M (+$77.2M) [Q4]

5% more funds holding

Funds holding: 138 [Q3] → 145 (+7) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 3 [Q3] → 3 (+0) [Q4]

0.25% less ownership

Funds ownership: 109.3% [Q3] → 109.05% (-0.25%) [Q4]

7% less call options, than puts

Call options by funds: $2.28M | Put options by funds: $2.46M

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $22 231% upside
• Avg. target: $28 314% upside
• High target: $33 397% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

Chardan Capital Daniil Gataulin 20% 1-year accuracy 10 / 50 met price target	397% upside $33	Buy Maintained	6 Mar 2025
HC Wainwright & Co. Yi Chen 31% 1-year accuracy 53 / 171 met price target	231% upside $22	Buy Reiterated	6 Mar 2025